Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$73.78 USD
+0.40 (0.55%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $73.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Merit Medical (MMSI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$91.67 | $112.00 | $81.00 | 24.93% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Merit Medical comes to $91.67. The forecasts range from a low of $81.00 to a high of $112.00. The average price target represents an increase of 24.93% from the last closing price of $73.38.
Analyst Price Targets (9 )
Broker Rating
Merit Medical currently has an average brokerage recommendation (ABR) of 1.78 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.75 a month ago based on eight recommendations.
Of the nine recommendations deriving the current ABR, four are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 44.44% and 33.33% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 3 | 3 | 2 | 2 | 2 |
Hold | 2 | 2 | 2 | 2 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.78 | 1.78 | 1.75 | 1.75 | 1.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/11/2024 | C.L. King & Associates | Kristen M Stewart | Not Available | Moderate Buy |
2/29/2024 | Canaccord Genuity | William J Plovanic | Strong Buy | Strong Buy |
2/29/2024 | Barrington Research | Michael J Petusky | Strong Buy | Strong Buy |
2/29/2024 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
1/30/2024 | Raymond James | Jayson T Bedford | Moderate Buy | Moderate Buy |
1/12/2024 | Piper Sandler | Jason Bednar | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.78 |
ABR (Last week) | 1.78 |
# of Recs in ABR | 9 |
Average Target Price | $91.67 |
LT Growth Rate | 10.80% |
Industry | Medical - Dental Supplies |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | 0.71 |